NovaGo Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $29.7M

  • Investors
  • 6

NovaGo Therapeutics General Information

Description

Developer of human antibody therapeutics intended to enhance nerve growth and regeneration for patients with spinal cord injuries. The company's therapy focuses on blocking the Nogo-A receptor, which inhibits nerve growth, thereby facilitating nerve repair and improving functional recovery, enabling healthcare providers to offer advanced treatment options for individuals affected by severe neurological disorders.

Contact Information

Formerly Known As
CeNeReg
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Wagistrasse 27
  • Schlieren
  • 8952 Zürich
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Wagistrasse 27
  • Schlieren
  • 8952 Zürich
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NovaGo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 31-Aug-2026 $29.7M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) Cancelled Clinical Trials - Phase 1
3. Early Stage VC (Series A) 04-Mar-2019 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2016 Completed Clinical Trials - Phase 1
1. University Spin-Out 01-Jan-2015 Completed Pre-Clinical Trials
To view NovaGo Therapeutics’s complete valuation and funding history, request access »

NovaGo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
To view NovaGo Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NovaGo Therapeutics Patents

NovaGo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026041734-A1 Methods for treating neurological disorders using anti-nogo-a antibodies Pending 22-Aug-2024
US-12662528-B2 Anti-nogo-a antibodies and methods of making and using thereof Active 24-Oct-2019
AU-2020370751-A1 Novel anti-nogo-a antibodies Pending 24-Oct-2019
CA-3158491-A1 Novel anti-nogo-a antibodies Pending 24-Oct-2019
EP-4048692-A2 Novel anti-nogo-a antibodies Pending 24-Oct-2019 C07K16/22
To view NovaGo Therapeutics’s complete patent history, request access »

NovaGo Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NovaGo Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Swiss Paraplegic Foundation Corporation
The Wings for Life foundation Corporation
Kinled Holding Family Office Minority
Neurimmune Corporation Minority
Pureos Bioventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

NovaGo Therapeutics FAQs

  • When was NovaGo Therapeutics founded?

    NovaGo Therapeutics was founded in 2015.

  • Where is NovaGo Therapeutics headquartered?

    NovaGo Therapeutics is headquartered in Zürich, Switzerland.

  • What is the size of NovaGo Therapeutics?

    NovaGo Therapeutics has 10 total employees.

  • What industry is NovaGo Therapeutics in?

    NovaGo Therapeutics’s primary industry is Drug Discovery.

  • Is NovaGo Therapeutics a private or public company?

    NovaGo Therapeutics is a Private company.

  • What is NovaGo Therapeutics’s current revenue?

    The current revenue for NovaGo Therapeutics is .

  • How much funding has NovaGo Therapeutics raised over time?

    NovaGo Therapeutics has raised $41.4M.

  • Who are NovaGo Therapeutics’s investors?

    Swiss Paraplegic Foundation, The Wings for Life foundation, Kinled Holding, Neurimmune, and Pureos Bioventures are 5 of 6 investors who have invested in NovaGo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process